171 related articles for article (PubMed ID: 22584948)
1. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.
Kanakkanthara A; Rawson P; Northcote PT; Miller JH
Pharm Res; 2012 Nov; 29(11):3022-32. PubMed ID: 22584948
[TBL] [Abstract][Full Text] [Related]
2. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
[TBL] [Abstract][Full Text] [Related]
3. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
Kanakkanthara A; Northcote PT; Miller JH
Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
[TBL] [Abstract][Full Text] [Related]
4. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
[TBL] [Abstract][Full Text] [Related]
5. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
[TBL] [Abstract][Full Text] [Related]
7. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV
J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
[TBL] [Abstract][Full Text] [Related]
8. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
9. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
10. Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration.
Field JJ; Northcote PT; Paterson I; Altmann KH; Díaz JF; Miller JH
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467385
[TBL] [Abstract][Full Text] [Related]
11. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
[TBL] [Abstract][Full Text] [Related]
12. Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells.
Chan A; Singh AJ; Northcote PT; Miller JH
Invest New Drugs; 2016 Aug; 34(4):424-38. PubMed ID: 27155614
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.
Hanna R; Maass DR; Atkinson PH; Northcote PT; Teesdale-Spittle PH; Bellows DS; Miller JH
Mol Biosyst; 2014 Jan; 10(1):110-6. PubMed ID: 24161989
[TBL] [Abstract][Full Text] [Related]
14. Laulimalide and peloruside A inhibit mitosis of Saccharomyces cerevisiae by preventing microtubule depolymerisation-dependent steps in chromosome separation and nuclear positioning.
Best HA; Matthews JH; Heathcott RW; Hanna R; Leahy DC; Coorey NV; Bellows DS; Atkinson PH; Miller JH
Mol Biosyst; 2013 Nov; 9(11):2842-52. PubMed ID: 24056987
[TBL] [Abstract][Full Text] [Related]
15. Cellular effects of the microtubule-targeting agent peloruside A in hypoxia-conditioned colorectal carcinoma cells.
Řehulka J; Annadurai N; Frydrych I; Znojek P; Džubák P; Northcote P; Miller JH; Hajdúch M; Das V
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1833-1843. PubMed ID: 28366502
[TBL] [Abstract][Full Text] [Related]
16. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
Escuin D; Kline ER; Giannakakou P
Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
[TBL] [Abstract][Full Text] [Related]
17. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
18. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
[TBL] [Abstract][Full Text] [Related]
20. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.
Das V; Miller JH
Brain Res; 2012 Dec; 1489():121-32. PubMed ID: 23085090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
